BOCA RATON, Fla., Aug. 29 /PRNewswire/ -- Dawson James Securities, a full- service investment firm serving the healthcare and biotechnology industry, initiated research coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy rating and a 12-18 month price target of $6.00. John M. Putnam, Sr. VP-Medical Devices, issued the report.
The report describes CryoCor's recently FDA-approved cryoablation system for atrial flutter and their current pivotal trial for atrial fibrillation. Mr. Putnam states "With the FDA's approval of CryoCor's cryoablation system for the treatment of atrial flutter, and the strong prospect of an approval for treating the much larger indication of atrial fibrillation in 2008, we believe the company is on the verge of meaningful revenue generation."
A copy of the report may be obtained by contacting Dawson James Securities at 561-391-5555.
About Dawson James Securities:
Dawson James Securities is a full service investment firm with deep expertise in healthcare and biotechnology and having a staff of over 50 investment professionals providing institutional research, investment banking and high net worth services to our clients. More information is available at http://www.DawsonJames.com
Dawson James has not acted as an investment banker for the company mentioned in this report in the past, although Dawson James may have sought in the past, or may actively seek in the future, compensation for investment banking services. Dawson James and/or its directors and employees may own securities in the companies and may increase or decrease holdings in the future.
The analyst certifies that 1) all o
|SOURCE Dawson James Securities|
Copyright©2007 PR Newswire.
All rights reserved